Siegfried to Buy Early-Phase CDMO Site from Curia

Zofingen, Switzerland-based contract development and manufacturing organization (CDMO) Siegfried has signed a binding agreement to acquire an early-phase CDMO site in Grafton, Wisconsin, US, from Curia. The transaction is expected to close by July 1, subject to customary closing conditions.

The new site, which specializes in early-phase development and manufacturing services with a team of more than 80 employees, is set to strengthen Siegfried’s customer offering for drug substances in terms of capabilities and geographical coverage, the company said. Siegfried intends to develop the site into a best-in-class hub for early-phase CDMO services for its global customer base, including services for projects with highly potent APIs.

Reto Suter, interim CEO and CFO of Siegfried, said: “Siegfried now offers an integrated range of services from early-stage development to commercial production of APIs through to the manufacturing of fully formulated drug products.”

The acquisition, the Swiss CDMO said, will strengthen its position in the US, enable the company to provide comprehensive support to customers in the pre-clinical and clinical development and manufacturing of drug substances, and further strengthen its drug substance pipeline.

The acquisition is financed from existing funds. The outlook for 2024 and the mid-term financial targets remain unchanged, Siegfried commented.

© werbefoto-burger.ch - stock.adob
© werbefoto-burger.ch - stock.adob

Company

Logo:

Siegfried

Untere Brühlstr. 4
4800 Zofingen
Switzerland

Company contact







CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.